US EditionWHO set to back use of weight-loss drugs for adults globally: Reuters
- The World Health Organization plans to officially recommend weight-loss drugs for adults worldwide this August, marking a shift in obesity treatment.
- This change follows growing obesity rates affecting over a billion people globally, with about 70% living in low- and middle-income countries.
- The drugs, known as GLP-1 receptor agonists, include brands like Wegovy and Zepbound and work by mimicking a hormone that slows digestion and increases fullness.
- Clinical trials showed weight loss of 15% to 20% depending on the drug, but the medicines cost over $1,000 monthly, raising concerns about affordability and side effects.
- If added to the WHO Essential Medicines List, these drugs could see broader access through large-scale programs and generic versions as patents expire next year.
22 Articles
22 Articles
Malay Mail
AlKhaleej TodayWHO set to back weight-loss drugs for adults worldwide, seeks affordability solutions
LONDON, May 1 — The World Health Organisation plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters today shows, marking a shift in its approach to treating the global health problem. The UN agency also called for strategies to improve access to the treatment in low- and middle-income countries. More than a billion people now have obesity worldwide, according to the WHO, a…
WHO set to back use of weight-loss drugs for adults globally, raises cost issue
The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a shift in its approach to treating the global health problem.
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
